E-LIB Suche - Ergebnisse für: Choueiri, T.

1

The impact of COVID-19 on cancer care and oncology clinical..:

Sessa, C ; Cortes, J ; Conte, P...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.esmoop.2021.100339. , 2022

Link: https://serval.unil.ch/n..

2

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Eve..:

Choueiri, T ; Suárez Rodríguez, Cristina ; Hainsworth, John...
The Oncologist;27(12). , 2022

Link: https://hdl.handle.net/1..

3

CheckMate-9ER-Studie: Nivolumab + Cabozantinib im Vergleich..:

Bedke, J ; Choueiri, T ; Powles, T...
http://dx.doi.org/10.3205/21swdgu23. , 2021

Link: https://doi.org/10.3205/..

4

The impact of COVID-19 on cancer care and oncology clinical..:

Sessa, C ; Cortés Castan, Javier ; Conte, P...
ESMO Open;7(1). , 2021

Link: https://hdl.handle.net/1..

5

METEOR Studie: Analyse des Gesamtüberlebens (OS) basierend ..:

Goebell, P ; Duran, I ; Maroto, P...
http://dx.doi.org/10.3205/20urobay019. , 2020

Link: https://doi.org/10.3205/..

6

METEOR Studie: Retrospektive Analyse von Patienten mit fort..:

Schönheit, J ; Powles, T ; Tannir, N...
Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, Choueiri TK. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol. 2016 Sep;34(27):3267-75. DOI:10.1200/JCO.2016.66.7931. , 2018

Link: https://doi.org/10.3205/..

7

Guidelines for the definition of time-to-event end points i..:

Kramar A ; Negrier S ; Sylvester R...
info:eu-repo/semantics/altIdentifier/pmid/26371288. , 2015

Link: http://hdl.handle.net/11..

8

Definition and validation of "favorable high-risk prostate ..:

Muralidhar, V ; Chen, M ; Reznor, G...
International Journal of Radiation: Oncology - Biology - Physics, 2015; 93(4):828-835. , 2015

Link: http://hdl.handle.net/24..

9

Prognostic significance of absolute lymphocyte count in pat..:

Takemura, K ; Yuasa, T ; Lemelin, A...
https://pure.au.dk/portal/en/publications/3cf57fe9-e8f4-477e-b806-a6a7b47208a2. , 2024

Link: https://pure.au.dk/porta..

10

Nivolumab plus cabozantinib versus sunitinib for first-line..:

Powles, T ; Burotto, M ; Escudier, B...
Powles , T , Burotto , M , Escudier , B , Apolo , A B , Bourlon , M T , Shah , A Y , Suárez , C , Porta , C , Barrios , C H , Richardet , M , Gurney , H , Kessler , E R , Tomita , Y , Bedke , J , George , S , Scheffold , C , Wang , P , Fedorov , V , Motzer , R J & Choueiri , T K 2024 , ' Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma : extended follow-up from the phase III randomised CheckMate 9ER trial ' , ESMO Open , vol. 9 , no. 5 , 102994 , pp. 1-11 . https://doi.org/10.1016/j.esmoop.2024.102994. , 2024

Link: https://researchers.mq.e..

11